HLA Protein Technologies (Oklahoma City, OK) develops and manufactures validated, mammalian-expressed soluble HLA Class I and II molecules and offers a comprehensive suite of related assay services: quantitative peptide-binding (IC₅₀) validation, focused peptide-library screening, T-cell epitope mapping, custom HLA–peptide reagent production, and transplant antibody-monitoring platform development. For more than 20 years, we’ve produced endogenously loaded HLA proteins that retain native conformation and physiologic peptide occupancy, supporting oncology, vaccine, transplant, and translational immunology programs.
Our industrialized production includes over 125 Class I and 150 Class II molecules in unmodified and biotinylated formats, delivered with lot-traceable QC, standardized SOPs, and assay-transfer-ready workflows. These reagents and services enable robust target validation, reproducible HLA-restriction assignments, reliable antibody-specificity assessment, and accelerated assay development for research labs, CROs, and biopharma teams. Visit hlaprotein.com to explore our products and services.
